Mirdametinib not checked
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany · PD-0325901
FollowEvery change as it happens, and a Monday email
Trials
3 active
5 in total · 1 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
- How it’s given
- “Mirdametinib will be administered as a single, oral, 4 mg dose in the morning on Day 1 for each study participant enrolled in the study.”In the company’s words, NCT06997276 on ClinicalTrials.gov
- Tested for
- Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1), Hepatic Impairment, Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
- Main trialPhase 2
- “This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up phase.”In the company’s words, NCT03962543 on ClinicalTrials.gov
- Other names
- PD-0325901
Other drugs for Plexiform Neurofibroma
- TQ-B3234Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- LuvometinibShanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Phase 3
- SelumetinibAstraZeneca · Phase 3
- HLX-1502Healx Limited · Phase 2
- TunlametinibShanghai Kechow Pharma, Inc. · Phase 2
- PAS-004Pasithea Therapeutics Corp. · Phase 1
Coming up2
- 27 NovPhase 1 trial completes · ClinicalTrials.gov
- 21 Oct 2032Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 13 NovCompletion date moved: 2026-10-31 to 2026-11-27 · ClinicalTrials.gov NCT06997276
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 20 Sep 2023 | MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | |
| Phase 1Recruiting | 27 Nov 2026 | Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib | |
| Phase 1Not yet recruiting | 21 Oct 2032 | A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | |
| Phase 1/2Terminated | 15 Jan 2025 | Mirdametinib + BGB-3245 in Advanced Solid Tumors | |
| Phase 1Completed | 27 Feb 2026 | To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026